Status:
TERMINATED
Stem Cell Transplantation for Fanconi Anemia
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Conditions:
Fanconi Anemia
Eligibility:
All Genders
1-18 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine whether thymic shielding during total body irradiation can be given and whether it will reduce the risk of infections in Fanconi Anemia patients undergoing al...
Detailed Description
All subjects will be given the same treatment regimen of total body irradiation (TBI), Fludarabine, Cyclophosphamide, and anti-thymocyte globulin (ATG), followed by an alternate donor stem cell transp...
Eligibility Criteria
Inclusion
- Patients must be less than (\<) 18 years of age with a diagnosis of Fanconi anemia.
- Patients must have an HLA-A, B, DRB1 identical unrelated donor or less than or equal to (≤)1 antigen mismatched related (non-HLA-matched sibling) or \<1 antigen mismatched unrelated UCB donor. Patients and donors will be typed for HLA-A and B using serological or molecular techniques and for DRB1 using high resolution molecular typing.
- Patients with FA must have aplastic anemia (AA), myelodysplastic syndrome without excess blasts, or high risk genotype as defined below.
- Aplastic anemia is defined as having at least one of the following when not receiving growth factors or transfusions
- Platelet count \<20 x 10\^9/L
- ANC \<5 x 10\^8/L
- Hgb \<8 g/dL
- Myelodysplastic syndrome with multilineage dysplasia with or without chromosomal anomalies
- High risk genotype (e.g. IVS-4 or exon 14 FANCC mutations, or BRCA1 or 2 mutations)
- Adequate major organ function including
- Cardiac: ejection fraction greater than (\>)45%
- Hepatic: bilirubin, AST/ALT, ALP \<2 x normal
- Karnofsky performance status \>70% or Lansky performance status \>50%
- Women of child-bearing age must be using adequate birth control and have a negative pregnancy test
Exclusion
- Available HLA-genotypically identical related donor
- History of gram negative sepsis or systemic fungal infection (proven or suspected based on radiographic studies)
- Refractory anemia with excess blasts, or leukemia
- Active central nervous system (CNS) leukemia at time of hematopoietic cell transplant (HCT)
- History of squamous cell carcinoma of the head/neck/cervix within 2 years of HCT
- Pregnant or lactating female
- Prior radiation therapy preventing use of total body irradiation (TBI) 450 centigray (cGy)
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00167206
Start Date
March 1 2004
End Date
December 1 2008
Last Update
August 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States, 55455